nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.10.2014 | Original Article

The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma

verfasst von: Ana S. Soares, Vera M. Costa, Carmen Diniz, Paula Fresco

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metastatic melanoma is considered one of the most aggressive malignant tumours, representing the deadliest form of skin cancer. Melanoma progression is associated with the abrogation of normal controls that limit cell proliferation, migration, and invasion, eventually leading to metastasis. Based on the variety of cellular mechanisms involved in metastatic progression, we aimed to evaluate the effect of inosine (50 μM) and of the combination of Cl-IB-MECA (10 μM) with paclitaxel (10 ng/mL) on several stages of melanoma progression.

Methods

Proliferation, migration, adhesion, invasion, and colony formation assays were performed on human C32 and A375 metastatic melanoma cells. Levels of ERK1/2 were also determined using an ELISA kit. Moreover, mouse aortic rings were treated with vascular endothelial growth factor in order to assess the microvessel sprouting (an indicator of angiogenesis) in the presence of the referred compounds.

Results

We demonstrate that inosine induced, through A₃ adenosine receptor activation, proliferation, migration, adhesion, and invasion on C32 and A375 melanoma cells, although with dissimilar importance on the two melanoma cell lines. Inosine also increased colony formation on A375 cells. Levels of ERK1/2 were increased after inosine exposure and that increase was dependent on A₃ adenosine receptor activation in both cell lines. Moreover, microvessel sprouting stimulated by inosine was decreased by the combination of Cl-IB-MECA with paclitaxel.

Conclusions

Cl-IB-MECA combined with paclitaxel was able to impair almost all of the referred metastatic related mechanisms induced by inosine, making this approach a valuable tool for combinatory therapy against metastatic melanoma.

Bandarchi B, Ma L, Navab R, Seth A, Rasty G (2010) From melanocyte to metastatic malignant melanoma. Dermatol Res Pract 2010. doi:10.1155/2010/583748

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRef

Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology 23(6):488–496PubMedPubMedCentral

Soares AS, Costa VM, Diniz C, Fresco P (2013) Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: a new possible therapeutic strategy for melanoma. Biomed Pharmacother 67(8):777–789PubMedCrossRef

Soares AS, Costa VM, Diniz C, Fresco P (2014) Combination of Cl-IB-MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR-dependent autophagy and mitotic catastrophe on human melanoma cells. J Cancer Res Clin Oncol. doi:10.1007/s00432-014-1645-z PubMed

Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA (2012) NF-kappaB as potential target in the treatment of melanoma. J Transl Med 10:53. doi:10.1186/1479-5876-10-53 PubMedCrossRefPubMedCentral

Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10(2):153–163PubMedCrossRef

Haass NK, Smalley KS, Li L, Herlyn M (2005) Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res Spons Eur Soc Pigment Cell Res Int Pigment Cell Soc 18(3):150–159CrossRef

Attoub S, Arafat K, Gelaude A, Al Sultan MA, Bracke M, Collin P, Takahashi T, Adrian TE, De Wever O (2013) Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis. PLoS One 8(1):e53087PubMedCrossRefPubMedCentral

10.

Huang YW, Baluna R, Vitetta ES (1997) Adhesion molecules as targets for cancer therapy. Histol Histopathol 12(2):467–477PubMed

11.

Yamazoe Y, Tsubaki M, Matsuoka H, Satou T, Itoh T, Kusunoki T, Kidera Y, Tanimori Y, Shoji K, Nakamura H, Ogaki M, Nishiura S, Nishida S (2009) Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int 33(10):1087–1094PubMedCrossRef

12.

Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR (2009) Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28(31):2796–2805PubMedCrossRefPubMedCentral

13.

Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Update Rev Comment Antimicrob Anticancer Chemother 13(1–2):16–28CrossRef

14.

Spychala J (2000) Tumor-promoting functions of adenosine. Pharmacol Ther 87(2–3):161–173PubMedCrossRef

15.

Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ (2011) CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71(8):2892–2900PubMedCrossRef

16.

Di Virgilio F (2012) Purines, purinergic receptors, and cancer. Cancer Res 72(21):5441–5447PubMedCrossRef

17.

Soares AS, Costa VM, Diniz C, Fresco P (2014) Inosine strongly enhances human C32 melanoma cells proliferation through PLC-PKC-MEK1/2-ERK1/2 and PI3K pathways. Basic Clin Pharmacol Toxicol. doi:10.1111/bcpt.12280

18.

Vannoni D, Bernini A, Carlucci F, Civitelli S, Di Pietro MC, Leoncini R, Rosi F, Tabucchi A, Tanzini G, Marinello E (2004) Enzyme activities controlling adenosine levels in normal and neoplastic tissues. Med Oncol 21(2):187–195PubMedCrossRef

19.

Linden J (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41:775–787PubMedCrossRef

20.

Pirincci N, Gecit I, Gunes M, Yuksel MB, Kaba M, Tanik S, Demir H, Aslan M (2012) Serum adenosine deaminase, catalase and carbonic anhydrase activities in patients with bladder cancer. Clinics 67(12):1443–1446PubMedCrossRefPubMedCentral

21.

Aghaei M, Karami-Tehrani F, Salami S, Atri M (2005) Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities. Clin Biochem 38(10):887–891PubMedCrossRef

22.

Zanini D, Schmatz R, Pelinson LP, Pimentel VC, da Costa P, Cardoso AM, Martins CC, Schetinger CC, Baldissareli J, do Carmo Araujo M, Oliveira L, Chiesa J, Morsch VM, Leal DB, Schetinger MR (2013) Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer. Mol Cell Biochem 374(1–2):137–148PubMedCrossRef

23.

Shafy A, Molinie V, Cortes-Morichetti M, Hupertan V, Lila N, Chachques JC (2012) Comparison of the effects of adenosine, inosine, and their combination as an adjunct to reperfusion in the treatment of acute myocardial infarction. ISRN Cardiol 2012:326809PubMedCrossRefPubMedCentral

24.

Schram KH (1998) Urinary nucleosides. Mass Spectrom Rev 17(3):131–251PubMedCrossRef

25.

Gessi S, Varani K, Merighi S, Cattabriga E, Avitabile A, Gavioli R, Fortini C, Leung E, Mac Lennan S, Borea PA (2004) Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol 65(3):711–719PubMedCrossRef

26.

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–63PubMedCrossRef

27.

Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329–333PubMedCrossRef

28.

Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, Batra SK (2007) MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 5(4):309–320PubMedCrossRef

29.

Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6 K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28(29):2621–2633PubMedCrossRefPubMedCentral

30.

Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D’Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K (2012) Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 7(1):89–104CrossRef

31.

Jin X, Shepherd RK, Duling BR, Linden J (1997) Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Investig 100(11):2849–2857PubMedCrossRefPubMedCentral

32.

Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 107(4):1547–1552PubMedCrossRefPubMedCentral

33.

Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, Borea PA (2002) Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119(4):923–933PubMedCrossRef

34.

Wolber C, Fozard JR (2005) The receptor mechanism mediating the contractile response to adenosine on lung parenchymal strips from actively sensitised, allergen-challenged Brown Norway rats. Naunyn-Schmiedeberg’s Arch Pharmacol 371(2):158–168CrossRef

35.

Mlejnek P, Dolezel P, Frydrych I (2013) Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations. J Physiol Biochem 69(3):405–417PubMedCrossRef

36.

Mervic L (2012) Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One 7(3):e32955PubMedCrossRefPubMedCentral

37.

Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC Jr (2011) Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Res 71(17):5806–5817PubMedCrossRefPubMedCentral

38.

Tran TA, Gillet L, Roger S, Besson P, White E, Le Guennec JY (2009) Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness. Biochem Biophys Res Commun 379(2):304–308PubMedCrossRef

39.

Ohkawa Y, Miyazaki S, Hamamura K, Kambe M, Miyata M, Tajima O, Ohmi Y, Yamauchi Y, Furukawa K, Furukawa K (2010) Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem 285(35):27213–27223PubMedCrossRefPubMedCentral

40.

Sadej R, Spychala J, Skladanowski AC (2006) Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res 16(3):213–222PubMedCrossRef

41.

Wang F, Cao Y, Liu HY, Xu SF, Han R (2003) Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells. J Asian Nat Prod Res 5(2):121–129PubMedCrossRef

42.

Locatelli C, Leal PC, Yunes RA, Nunes RJ, Creczynski-Pasa TB (2009) Gallic acid ester derivatives induce apoptosis and cell adhesion inhibition in melanoma cells: the relationship between free radical generation, glutathione depletion and cell death. Chem Biol Interact 181(2):175–184PubMedCrossRef

43.

Sallam AA, Ramasahayam S, Meyer SA, El Sayed KA (2010) Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration. Bioorgan Med Chem 18(21):7446–7457CrossRef

44.

Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P (2013) CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist 18(1):25–26PubMedCrossRefPubMedCentral

45.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA (2005) A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280(20):19516–19526PubMedCrossRef

46.

Conner SR, Scott G, Aplin AE (2003) Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem 278(36):34548–34554PubMedCrossRef

47.

Romanchikova N, Trapencieris P, Zemitis J, Turks M (2013) A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation. J Enzyme Inhib Med Chem. doi:10.3109/14756366.2013.855207 PubMed

48.

Bar-Yehuda S, Madi L, Silberman D, Gery S, Shkapenuk M, Fishman P (2005) CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 7(1):85–90PubMedCrossRefPubMedCentral

49.

Sung SY, Hsieh CL, Wu D, Chung LW, Johnstone PA (2007) Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 31(2):36–100PubMedCrossRef

50.

Kim GD, Oh J, Jeong LS, Lee SK (2013) Thio-Cl-IB-MECA, a novel A(3) adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells. Biochem Biophys Res Commun 437(1):79–86PubMedCrossRef

Titel: The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma
verfasst von: Ana S. Soares
Vera M. Costa
Carmen Diniz
Paula Fresco
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2557-y

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901

Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy

Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study

Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie